ClinicalTrials.gg
Not yet recruitingNCT07805070Updated Sep 4, 2026

Uncovering Neurocognitive Mechanisms and Enhancement of Exposure-based Fear Learning With Cognitive Training

An interventional study of Cognitive training and Cognitive training in Anxiety and Fear Extinction, sponsored by University of California, San Diego. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Anxiety disorders remain are among the most prevalent psychiatric conditions and are associated with negative outcomes spanning poor health to increased suicide risk. While exposure therapy is recognized as a gold standard empirically supported treatment, many individuals fail to achieve adequate response. Exposure therapy is grounded in fear extinction learning models, which suggest that anxiety diminishes when individuals repeatedly confront their fears. To improve exposure-based interventions, it is critical to enhance our understanding of underlying mechanisms of fear extinction and how to better target these mechanisms. Fear extinction requires basic neurocognitive abilities that allow individuals to learn from and adapt to experiences confronting feared situations. Emerging cross sectional and experimental data suggest that working memory is a particularly important neurocognitive process that is associated with fear learning outcomes. By enhancing working memory through experimental manipulations like cognitive training, we may improve the fear extinction learning processes essential for successful exposure therapy. Unlike other neurocognitive enhancements (e.g., medications), computer-based working memory training offers high mechanistic precision, ease of administration, and low cost. The long-term goal of this research is to develop a novel mechanistic understanding of the neurocognitive processes involved in exposure-based fear extinction learning, ultimately aiming to improve interventions for anxiety disorders. This study will test the effects of manipulating working memory prior to a massed exposure paradigm, comparing working memory training plus massed exposure (WMT+Ex) to a sham training plus massed exposure (ST+Ex) condition. Using public speaking anxiety as a clinical exemplar, we will employ a rigorous experimental trial design combined with a validated single-visit speech exposure paradigm to assess fear extinction learning outcomes through multiple measures, including behavioral, physiological, neural, and self-report. The central hypothesis is that WMT+Ex will improve markers of fear extinction learning considered to underlie clinical response in exposure therapy. Specific aims are to 1) determine the extent to which working memory training delivered prior to massed exposure improves behavioral and neural markers of fear extinction learning, and 2) evaluate the effects of working memory training delivered prior to massed exposure on fear extinction learning occurring during exposure. This study is expected to achieve two goals: first, to advance our understanding of the neurocognitive mechanisms of fear extinction through a rigorous experimental design, and second, to validate a combined working memory training and exposure paradigm. If successful in enhancing fear extinction, this approach could be further explored in therapeutic formats to assess its clinical effects.

02

Conditions studied

  • Anxiety
  • Fear Extinction

Keywords

  • anxiety
  • social phobia
03

In context

Anxiety Disorders

7,201 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's planned enrollment of 120 is above the median of 80 across 6,057 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University of California, San Diego is the lead sponsor of 980 studies on the registry; 195 are open to participants now.

Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age 18-65
  2. fluent in English
  3. diagnosis of social anxiety disorder (generalized or performance-only) with Personal Report of Public Speaking Anxiety (PRPSA) score of ≥120 at screening
  4. 6-week stability if receiving other (non-anxiety focused) psychosocial treatment

Exclusion criteria

Exclusion Criteria:

  1. past 3-mo diagnosis of moderate or greater alcohol or substance use disorder
  2. lifetime history of psychotic or bipolar I disorders
  3. acute suicidality necessitating immediate clinical intervention
  4. neurodegenerative or neurodevelopmental disorders
  5. history of neurological condition
  6. conditions that are unsafe for MRI (e.g., metal in body)
  7. currently receiving psychosocial treatment for anxiety or related condition
  8. currently receiving psychiatric pharmacotherapy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Cognitive training

    Training to enhance cognitive functioning

    Behavioral: Cognitive training

  • Sham comparator
    Sham training

    Computer interface designed to control for general task parameters

    Behavioral: Cognitive training

Interventions

  • BehavioralCognitive training

    Repeated practice with cognitive skills to enhance performance

  • BehavioralCognitive training

    Sham cognitive training

06

What researchers measure

Primary outcomes

  1. Fear extinction

    threat expectancy ratings to the CS+ during late extinction learning

    Time frame: Change from baseline day 1 to post-intervention day 2

  2. Subjective Units of Distress

    Ratings of distress during speeches

    Time frame: Change from baseline speech to post speech (all within day 1)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — NIH NDA

Time frame: see NIH for details

Access criteria: see NIH for details

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07805070
Responsible party
Jessica Bomyea (Assoc Prof, University of California, San Diego) — Principal investigator
First posted
Sep 4, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 1, 2031 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion